Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2002 1
2015 1
2019 1
2021 2
2022 3
2023 4
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Dysbiotic microbiota interactions in Crohn's disease.
Caparrós E, Wiest R, Scharl M, Rogler G, Gutiérrez Casbas A, Yilmaz B, Wawrzyniak M, Francés R. Caparrós E, et al. Among authors: gutierrez casbas a. Gut Microbes. 2021 Jan-Dec;13(1):1949096. doi: 10.1080/19490976.2021.1949096. Gut Microbes. 2021. PMID: 34313550 Free PMC article. Review.
Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
Peyrin-Biroulet L, Chapman JC, Colombel JF, Caprioli F, D'Haens G, Ferrante M, Schreiber S, Atreya R, Danese S, Lindsay JO, Bossuyt P, Siegmund B, Irving PM, Panaccione R, Cao Q, Neimark E, Wallace K, Anschutz T, Kligys K, Duan WR, Pivorunas V, Huang X, Berg S, Shu L, Dubinsky M; SEQUENCE Study Group. Peyrin-Biroulet L, et al. N Engl J Med. 2024 Jul 18;391(3):213-223. doi: 10.1056/NEJMoa2314585. N Engl J Med. 2024. PMID: 39018531 Clinical Trial.
Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis.
Rodríguez-Moranta F, Argüelles-Arias F, Hinojosa Del Val J, Iborra Colomino M, Martín-Arranz MD, Menchén Viso L, Muñoz Núñez F, Ricart Gómez E, Sánchez-Hernández JG, Valdés-Delgado T, Guardiola Capón J, Barreiro-de Acosta M, Mañosa Ciria M, Zabana Abdo Y, Gutiérrez Casbas A. Rodríguez-Moranta F, et al. Among authors: gutierrez casbas a. Gastroenterol Hepatol. 2024 May;47(5):522-552. doi: 10.1016/j.gastrohep.2024.01.007. Epub 2024 Feb 2. Gastroenterol Hepatol. 2024. PMID: 38311005 Free article. English, Spanish.
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus.
D'Amico F, Magro F, Dignass A, Al Awadhi S, Gutierrez Casbas A, Queiroz NSF, Rydzewska G, Duk Ye B, Ran Z, Hart A, Jairath V, Fiorino G, Peyrin-Biroulet L, Danese S. D'Amico F, et al. Among authors: gutierrez casbas a. Expert Rev Gastroenterol Hepatol. 2024 Aug;18(8):421-430. doi: 10.1080/17474124.2024.2397650. Epub 2024 Sep 3. Expert Rev Gastroenterol Hepatol. 2024. PMID: 39225555 Review.
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel disease.
Calvo Moya M, Mesonero Gismero F, Suarez Ferrer C, Hernández-Camba A, Vásquez Carlón D, García Benasach F, Aguas Peris M, Delgado Oliva FJ, González-Lama Y, Millán Scheiding M, Alonso Sebastián I, Camacho Martel L, Gallardo Arriero V, Echarri Piudo A, Bella Castillo P, Cano Sanz N, Vera Mendoza MI, Serrano Labajos R, Valdivia Martínez A, Pérez Restoy L, Zabana Abdo Y, Mañosa Ciria M, Rodríguez-Moranta F, Barreiro-de Acosta M, Gutiérrez Casbas A; en representación de GETECCU. Calvo Moya M, et al. Among authors: gutierrez casbas a. Gastroenterol Hepatol. 2024 Aug-Sep;47(7):774-792. doi: 10.1016/j.gastrohep.2023.12.013. Epub 2024 Jan 11. Gastroenterol Hepatol. 2024. PMID: 38218430 Free article. Review. English, Spanish.
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.
Chaparro M, Hermida S, Acosta D, Fernández-Clotet A, Barreiro-de Acosta M, Hernández Martínez Á, Arroyo M, Bosca-Watts MM, Diz-Lois Palomares MT, Menchén L, Martínez Cadilla J, Leo-Carnerero E, Muñoz Villafranca C, Sierra-Ausín M, González-Lama Y, Riestra S, Sendra Rumbeu P, Cabello Tapia MJ, García de la Filia I, Vicente R, Ceballos D, Pajares Villarroya R, Ramírez de la Piscina P, Martín-Arranz MD, Ramos L, Ruiz-Cerulla A, Martínez-Pérez TJ, San Miguel Amelivia E, Calvet X, Huguet JM, Keco-Huerga A, Lorente Poyatos RH, Muñoz JF, Ponferrada-Díaz Á, Sicilia B, Delgado-Guillena P, Gómez Delgado E, Rancel-Medina FJ, Alonso-Galán H, Herreros B, Rivero M, Varela P, Bermejo F, García Sepulcre M, Gimeno-Pitarch L, Kolle-Casso L, Márquez-Mosquera L, Martínez Tirado P, Ramírez C, Sesé Abizanda E, Dueñas Sadornil C, Fernández Rosáenz H, Gutiérrez Casbas A, Madrigal Domínguez RE, Nantes Castillejo Ó, Ber Nieto Y, Botella Mateu B, Frago Larramona S, López Serrano P, Rubio Mateos JM, Torrá Alsina S, Iyo E, Fernández Forcelledo JL, Hernández L, Rodríguez-Grau MC, Monfort Miquel D, Van Domselaar M, López Ramos C, Ruiz Barcia MJ, Gisbert JP; ULISES study group. Chaparro M, et al. Among authors: gutierrez casbas a. Aliment Pharmacol Ther. 2024 Nov;60(10):1325-1338. doi: 10.1111/apt.18230. Epub 2024 Sep 17. Aliment Pharmacol Ther. 2024. PMID: 39287363
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study.
Chaparro M, Baston-Rey I, Fernández-Salgado E, González García J, Ramos L, Diz-Lois Palomares MT, Argüelles-Arias F, Iglesias Flores E, Cabello M, Rubio Iturria S, Núñez Ortiz A, Charro M, Ginard D, Dueñas Sadornil C, Merino Ochoa O, Busquets D, Iyo E, Gutiérrez Casbas A, Ramírez de la Piscina P, Boscá-Watts MM, Arroyo M, García MJ, Hinojosa E, Gordillo J, Martínez Montiel P, Velayos Jiménez B, Quílez Ivorra C, Vázquez Morón JM, María Huguet J, González-Lama Y, Muñagorri Santos AI, Amo VM, Martín-Arranz MD, Bermejo F, Martínez Cadilla J, Rubín de Célix C, Fradejas Salazar P, San Román AL, Jiménez N, García López S, Figuerola A, Jiménez I, Martínez Cerezo FJ, Taxonera C, Varela P, de Francisco R, Monfort D, Molina Arriero G, Hernández Camba A, García-Alonso FJ, Van Domselaar M, Pajares Villarroya R, Núñez A, Rodríguez Moranta F, Marín-Jiménez I, Robles Alonso V, Martín Rodríguez MDM, Camo-Monterde P, García Tercero I, Navarro Llavat M, Arias García L, Hervías Cruz D, Sulleiro S, Novella C, Vispo E, Barreiro-de Acosta M, Gisbert JP. Chaparro M, et al. Among authors: gutierrez casbas a. Inflamm Bowel Dis. 2022 Nov 2;28(11):1725-1736. doi: 10.1093/ibd/izab357. Inflamm Bowel Dis. 2022. PMID: 35166347 Free PMC article.
Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
Iborra M, Caballol B, Garrido A, Huguet JM, Mesonero F, Ponferrada Á, Arias García L, Boscá Watts MM, Fernández Prada SJ, Brunet Mas E, Gutiérrez Casbas A, Cerrillo E, Ordás I, Ruiz L, García de la Filia I, Escobar Ortiz J, Sicilia B, Ricart E, Domènech E, Nos P. Iborra M, et al. Among authors: gutierrez casbas a. J Crohns Colitis. 2024 Aug 22:jjae127. doi: 10.1093/ecco-jcc/jjae127. Online ahead of print. J Crohns Colitis. 2024. PMID: 39171615
Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study.
Casanova MJ, Nantes Ó, Varela P, Vela-González M, Rivero M, Sierra-Gabarda O, Riestra S, Barreiro-de Acosta M, Martín-Rodríguez MDM, Gargallo-Puyuelo CJ, Reygosa C, Muñoz R, de la Filia-Molina IG, Núñez-Ortiz A, Kolle L, Calafat M, Huguet JM, Iglesias-Flores E, Martínez-Pérez TJ, Bosch O, Duque-Alcorta JM, Frago-Larramona S, Van Domselaar M, González-Cosano VM, Bujanda L, Rubio S, Mancebo A, Castro B, García-López S, de Francisco R, Nieto-García L, Laredo V, Gutiérrez-Casbas A, Mesonero F, Leo-Carnerero E, Cañete F, Ruiz L, Gros B, Del Moral-Martínez M, Rodríguez C, Chaparro M, Gisbert JP. Casanova MJ, et al. Among authors: gutierrez casbas a. Aliment Pharmacol Ther. 2023 Jul;58(1):60-70. doi: 10.1111/apt.17525. Epub 2023 Apr 23. Aliment Pharmacol Ther. 2023. PMID: 37089065
20 results